Opdivo’s EU Colorectal Cancer Setback ‘More Than Offset’ By Potential Gains In Combination

Digital illustration of Cancer cell in colour background
BMS has withdrawn its EU Opdivo filing for colorectal cancer

More from New Products

More from Scrip